Reference

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365:217-223.
2. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
3. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-1010.
4. Ezzati M, Lopez AD, Rodgers A. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
5. O'Connor PJ. Improving medication adherence: Challenges for physicians, payers, and policy makers. Arch Intern Med 2006; 166:1802-1804.
6. Nelson MR, Reid CM, Ryan P, et al. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185:487-489
7. Mounier-Vehier C, Bernaud C, Cart6 A, et al. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am J Hypertens 1998; 11:478-486.
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
10. Paul R Conlin. Efficacy and safety of angiotensin receptor blockers: a review of losartan in essential hypertension. Current Therapeutic Research 2001; 62(2):79-91.
11. Chobanian AV, Bakris GL, Black HR, et al, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560- 2572.

12. Oparil S, Calhoun DA. The calcium antagonists in the 1990s. An overview. Am J Hyperten 1991; 4:396-405.
13. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: Putting the calcium antagonist scare into context. Ann Intern Med 1995; 123:888-889.
14. Kes S, Caglar N, Canberk A, et al. Treatment of mild-tomoderate hypertension with calcium channel blockers: A multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. Curt Med Res Opin 2003; 19:226-237.
15. Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: Comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens 2002; 20:333-338.
16. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990; 48:76-86.
17. Osterloh I. The safety of amlodipine. Am Heart J 1989; 118:1114-1119.
18. Park JY, Kim KA, Lee GS, et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther 2004; 26:715-723.
19. Sealy JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. Hypertension: Pathophysiology, Diagnosis, and Management 1990; 19:87-96.
20. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure. Evaluation of losartan in the elderly study, ELITE. Lancet 1997; 349:747-52.
21. Derasari HR, Gandhi TP, Goyal RK. Antihypertensive agents. Elements of pharmacology 2008; 12:275-86.
22. Roger Walker, Clive Edwards. Hypertension. Clinical Pharmacy and Therapeutics 2006; 3:265-278.
23. Malhotra P, Kumari S, Kumar R, Jain S, Sharma BK. Prevalence and determinants of hypertension in an un-industrialised rural population of North India. J Hum Hypertens 1999; 13(7):467-72.
24. Weir M R, Klaussen D R, Hanes D S. Antihypertensive drugs. The Kidney 2003; 41(5):2381–2451.

25. Xu B, Xiao-hong L, Lin G, Queen L, Ferro A. Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol 2002; 136(3):375–382.
26. Papadopoulos CL, Kokkas BA. Atrial natriuretic peptide contributes to the antihypertensive action of many drugs. Eur J Drug Metab Pharmacokinet 2003; 28(1):55–57.
27. Phillips RA, Kloner RA, Grimm RH, Weinberger M. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich) 2003; 5(1):17-23
28. Massimo V, Junren Z, Maxwell T, Rodriguez A, Gamboa R, Gomez-Fernandez R, et al. Comparison of the blood pressure-lowering effects and tolerability of losartan and amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 2003; 25(5):1469-89.
29. Renate T, Arnold V, Manfred S. Efficacy, Safety and Effects on hypertension-associated symptoms of losartan, alone or in combination with hydrochlorothiazide, vs. amlodipine in patients with mild-to-moderate hypertension. Cur Ther Res 1998; 59(6):325-40.
30. Suzzane O, Eliav B, Michelle E, Charles L, Arthur V, et al. Efficacy, tolerability and effects on quality of life of losartan, alone or with hydrochlorothiazide, vs. amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18(4):608-625.
31. John MF, Elijah S, Alan G, William EKs, Martin L, Howard P, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2000; 23(8):1193-1208.
32. Cindy BL, Kyle RF, Diana F, Janet EC, Rhonda PE, et al. Effect of amlodipine on systolic blood pressure. Clin Ther 2003; 25(1):35-57.
33. Wilson TW, Yves L, Colin CB. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. CMAJ 1998; 159:469-76.
34. Steven GC, Michael M, Sulekha K, James L, Reinilde H. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure:

COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30(4):587-604.

35. Sang HK, Young DK, Do-Sun L, Myeong HY, Young K, et al. To Assess the Effects of Amlodipine Camsylate Vs. Amlodipine Besylate in Korean Adults with Mild to Moderate Hypertension. Clin Ther 2007; 29:1924-1936.
36. Paul RC. Efficacy and safety of angiotensin receptor blockers: a review of losartan in essential hypertension. Current Therapeutic Research 2001; 62(2):79-91.
37. Osvaldo K, Wille O, Décio M, et al. Evaluation of Efficacy and Tolerability of the Fixed Combi nation of Amlodipine and Losartan in the Treatment of Essential Hypertension (LOTHAR study). Arq Bras Cardiol. 2006;86(1):39-51.
38. Hong BK, Park CG, Kim KS, Yoon MH, et al. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. Am J Cardiovascular Drugs. 2011; 12(3):189-95.
39. Seok MK, Jong CY, Shung CC, et al. Comparative Efficacy and Safety Profile of Amlodipine 5 mg/Losartan 50 mg Fixed-Dose Combination and Amlodipine 10 mg Monotherapy in Hypertensive Patients Who Respond Poorly to Amlodipine 5 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Noninferiority Study. Clinical Therapeutics, 2011; 33 (12): 1953-63.
40. Praga M, Andrade CF, Luño J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant, 2003;18(9):1806-13.
41. Nicholas JA, Chun L, et al. Randomized, Double-Blind, Controlled Study of Losartan in Children with Proteinuria. Clin J Am Soc Nephrol, 2010; 5: 417–24.
42. Robert AK, Joel N, et al. Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. Ann Pharmacother, 2008; 42(11):1552-1562.
43. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit. 2001; 6(2):63-72.
44. Yasuda G, Ando D, et al. Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy. Diabetes Care. 2005; 28(8):1862-8.

45. Park HC, Xu ZG, Choi S, et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant. 2003; 18(6):1115-21.
46. Pablo IG, Josep MC, et al. Effects of Losartan and Amlodipine on Intrarenal Hemodynamics and TGF-β1 Plasma Levels in a Crossover Trial in Renal Transplant Recipients. JASN. 2001; 12(4):822-827.
47. Park CG, Youn HJ, Chae SC, et al. Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. Am J Cardiovasc Drugs. 2011; 12(1):35-47.
48. Shimosawa T, Gohchi K, et al. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res. 2007; 30(9):831-7.
49. Gokhale N, Shahani S, et al. Efficacy and safety of losartan-amplodipine combination -an Indian postmarketing surveillance experience. J Indian Med Assoc. 2002; 100(3):207-8.
50. Webb NJ, Lam C, Shahinfar S, et al. Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant. 2011;26(8):2521-6.
51. Watanabe S, Okura T, Kurata M, The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther. 2006; 28(10):1677-85.
52. Volpe M, Junren Z, Maxwell T, et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther. 2003 May;25(5):1469-89.
53. Iino Y, Hayashi M, Kawamura T, et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27(1):21-30.